Predict your next investment

Rheostat Therapeutics company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Stage

Series A | Alive

Total Raised

$23M

Last Raised

$23M | 3 yrs ago

About Rheostat Therapeutics

Rheostat Therapeutics is a biotech company focused on the discovery of treatments for neurodegeneration, cognition and rare diseases.

Rheostat Therapeutics Headquarter Location

Cambridge, Massachusetts,

United States

Latest Rheostat Therapeutics News

The Dementia Discovery Fund’s Portfolio Company Caraway Therapeutics Establishes Collaboration with AbbVie to develop small molecule therapeutics targeting Parkinson’s disease and other neurodegenerative disorders

Jun 10, 2021

Search jobs 10-Jun-2021 The Dementia Discovery Fund’s Portfolio Company Caraway Therapeutics Establishes Collaboration with AbbVie to develop small molecule therapeutics targeting Parkinson’s disease and other neurodegenerative disorders   Boston, MA (US) and London (UK) – June 9, 2021. The Dementia Discovery Fund (DDF) is pleased to announce that Caraway Therapeutics, a portfolio company originally incubated and seeded by DDF and SV Health Investors, has signed an exclusive collaboration, license and option agreement with AbbVie (NYSE: ABBV) to develop and commercialize Caraway’s small molecule therapeutics targeting TMEM175. TMEM175 is a potassium ion channel critical to lysosomal function implicated in both Parkinson’s disease (PD) and other neurodegenerative disorders. Under the terms of the agreement, Caraway will receive an upfront cash payment of $17 million. After Caraway completes certain pre-clinical research and development activities for the collaboration program, AbbVie has an option to license the program and proceed into IND-enabling studies, clinical development, and commercialization. Caraway is eligible to receive up to $267 million in payments, including upfront and future option payments, and development milestones. Caraway is also eligible to receive additional regulatory and commercial milestones, tiered royalties on global commercial sales, and has the option to participate in product development in return for higher royalty rates. Further details of Caraway’s collaboration with AbbVie can be found in the press release issued by Caraway Therapeutics on their website: https://carawaytx.com/news/   Dr. Jonathan Behr, Partner at The Dementia Discovery Fund, and a Board Director of Caraway Therapeutics, said, “Today’s collaboration with AbbVie highlights the significant progress that Caraway Therapeutics has made since the company was started by DDF and SV Health investors in 2017 based on the insights and vision of its Co-Founders, including Venture Partner Tim Harris, now Chair of Caraway’s Scientific Advisory Board. We are confident that by working together with AbbVie, the company can continue to successfully develop novel small molecule therapeutics, targeting TMEM175, which are designed to bring important clinical benefits to patients with Parkinson’s disease and other neurodegenerative disorders.”   Editor Details

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Rheostat Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Rheostat Therapeutics is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.